INTRODUCTION
Inflammation is characterized symptomatically by pain, redness, and swelling; disordered or excessive inflammation also entails loss of function. This clinical pathology results from the release of inflammatory mediators, predominantly from activated leukocytes that migrate into the target area. Among the key inflammatory mediators are the nϪ6 eicosanoids, prostaglandin E 2 (PGE 2 ) and leukotriene B 4 (LTB 4 ), which are derived from the nϪ6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA; 20:4nϪ6) (1) . Also important are the cytokines, interleukin 1␤ (IL-1␤) and tumor necrosis factor ␣ (TNF-␣), and there is strong evidence for the involvement of TNF-␣ in the joint pathology of rheumatoid arthritis (2, 3) .
Many antiinflammatory pharmacotherapies are directed at inhibiting the production of these inflammatory mediators and thus possibilities exist for therapies that incorporate nϪ3 and nϪ9 dietary fatty acids. However, there are competitive interactions between dietary PUFAs; thus, in any examination of the effects of dietary nϪ3 or nϪ9 PUFAs, it is important to consider also the background dietary nϪ6 PUFAs.
POLYUNSATURATED FATTY ACIDS IN THE DIET
In the typical Western diet, 20-25-fold more nϪ6 fats than nϪ3 fats are consumed (4) . This predominance of nϪ6 fat is due to the abundance in the diet of linoleic acid (LA; 18:2nϪ6), which is present in high concentrations in soy, corn, safflower, and sunflower oils. By contrast, there is a low intake of the nϪ3 homologue of LA, ␣-linolenic acid (ALA; 18:3nϪ3), which is present in leafy green vegetables and in flaxseed and canola oils. Once ingested, the 18-carbon fatty acids are desaturated and elongated to 20-carbon nϪ6 fatty acids. LA is converted to AA and ALA is converted to eicosapentaenoic acid (EPA; 20:5nϪ3). Compared with LA, there is little dietary intake of AA and EPA, which are present in meat and fish, respectively.
LA and ALA are necessary for complete health and cannot be synthesized in vertebrates; therefore, they are essential fatty acids. As a consequence, the relative dietary amounts of nϪ6 and nϪ3 fatty acids are determinants of the relative cellular amounts of LA and ALA (Figure 1) .
Unlike the 18-carbon nϪ3 fatty acid ALA, oleic acid (18:1nϪ9), is consumed in substantial amounts in the typical Western diet and is not an essential fatty acid. There is little eicosatrienoic acid (ETA; 20:3nϪ9) in cell membranes, however, probably because of the overwhelming competition from dietary LA for the relevant desaturase and elongase enzymes (5) (Figure 1 ). (1) . Thus, the lipid mediators may be involved in the pain, redness, and swelling that occurs in acute inflammation.
AA is the progenitor of both PGE 2 and LTB 4 via the cyclooxygenase and 5-lipoxygenase enzymatic pathways, respectively. EPA, the nϪ3 homologue of AA, can inhibit AA metabolism competitively via these enzymatic pathways and, thus, can suppress production of the nϪ6 eicosanoid inflammatory mediators. EPA is a potential cyclooxygenase substrate for the synthesis of PGE 3 , which also has inflammatory activity, although PGE 3 synthesis occurs with low efficiency or not at all (6, 7) . EPA is also a 5-lipoxygenase substrate and can lead to the formation of LTB 5 , but LTB 5 has little inflammatory activity compared with LTB 4 (8, 9) . Thus, increasing dietary nϪ3 fats can shift the balance of the eicosanoids produced to a less inflammatory mixture (Figure 2 ).
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JAMES ET AL There is potential also for use of dietary ETA for antagonism of AA conversion to LTB 4 . ETA is a substrate of 5-lipoxygenase and although LTA 3 formation occurs, LTA 3 is a poor substrate but a good inhibitor of leukotriene-A 4 hydrolase, the enzyme necessary for LTB 4 synthesis in addition to arachidonate 5-lipoxygenase (10, 11) . Inhibition of LTB 4 synthesis via inhibition of leukotriene-A 4 hydrolase has been observed in rats (12) and humans (13) during severe LA restriction, leading to elevated ETA concentrations. Furthermore, when ETA was included in the diet of (LA-sufficient) rats, it was incorporated into cell membranes and inhibited LTB 4 synthesis via inhibition of leukotriene-A 4 hydrolase (14-16). Thus, in partial analogy to the situation with EPA, increasing dietary ETA intake can also alter the balance of eicosanoids produced by leukocytes toward a potentially less inflammatory mixture (Figure 2 ). The effect of ETA on prostaglandin-endoperoxide synthase (cyclooxygenase) is less clear than that with 5-lipoxygenase. ETA lacks the nϪ6 double bond necessary for prostanoid formation, but may inhibit PGE 2 production because inhibition of endothelial PGI 2 production has been attributed to ETA (17) .
EFFECT OF DIETARY nϪ3 FATS ON PEPTIDE (CYTOKINE) INFLAMMATORY MEDIATORS
The cytokines IL-1␤ and TNF-␣ have proinflammatory cellular actions that include stimulating the production of collagenases (2, 18) and increasing the expression of adhesion molecules necessary for leukocyte extravasation (19) . More direct biological evidence for the importance of these cytokines in inflammatory joint disease includes the observations that intraarticular IL-1␤ causes arthritis in rabbits (20) , that mice transgenic for a modified human TNF gene that is constitutively expressed develop polyarthritis that is prevented by anti-TNF monoclonal antibody (21) , and that intravenous administration of anti-TNF-␣ monoclonal antibody to patients with rheumatoid arthritis suppresses joint inflammation (3) . Whereas the eicosanoids may mediate much of the early pathology of inflammatory joint disease, such as swelling, pain, and leukocyte infiltration, cytokines have been implicated in the late, destructive phase of the disease, which includes cartilage loss, bone resorption, and, ultimately, joint failure (2) .
Inclusion of nϪ3 fats in the diet can suppress the production of both TNF-␣ and IL-1␤. Fish oil is rich in the 20-carbon and 22-carbon nϪ3 fatty acids, EPA and docosahexaenoic acid (DHA; 22:6nϪ3) and it has been shown that dietary supplementation with encapsulated fish oil results in decreased monocyte synthesis of TNF-␣, IL-1␤, or both in healthy subjects (22) (23) (24) and in patients with rheumatoid arthritis (25) . Results of these studies are summarized in Table 1 . Although it is known that fish-oil ingestion effectively elevates cellular concentrations of EPA and DHA, it is not known whether EPA, DHA, or both are involved in the suppression of cytokine production.
An alternate approach to elevating cellular EPA concentrations is to increase intake of ALA, the progenitor of EPA. When flaxseed oil, which contains Ϸ56% ALA, was used by healthy male volunteers in their domestic food preparation, leukocyte EPA concentrations were increased and both IL-1␤ and TNF-␣ production were suppressed by Ϸ30% after 4 wk (Figure 3) (24) .
The successful application of any of these dietary approaches to suppressing excessive cytokine production in inflammatory disease rests in our knowledge of the dose-response relations and the mechanisms of action of nϪ3 fatty acids in the suppression of cytokine production. Regarding the first of these issues, there is an inverse exponential relation between mononuclear cell EPA content and cytokine production. Whether the cellular source of EPA is the diet or endogenous synthesis from dietary ALA, cytokine synthesis decreases as cellular EPA concentrations increase to Ϸ1% of total membrane fatty acids. Further increases in EPA content, however, do not result in further measurable decreases in cytokine production (Figure 4) (24) .
The mechanisms responsible for the suppression of cytokine production by nϪ3 fatty acids remain unknown, although suppression of eicosanoid production by nϪ3 fatty acids may be involved. Ingestion of nϪ3 fatty acids leads to suppression of thromboxane A 2 (TXA 2 ) synthesis by platelets and by gradient preparations of blood mononuclear cells (24) . In the mononuclear cell preparations, the TXA 2 is derived from contaminating platelets but also from the monocytes, where it is a major eicosanoid product (26) . When TXA 2 , but not PGE 2 , synthesis was inhibited in purified human monocytes, TNF-␣ and IL-1␤ synthesis were inhibited and the inhibition was overcome by the addition of an active TXA 2 analogue. Also, cytokine synthesis was inhibited by TXA-receptor antagonists. Collectively, these results provide evidence of a role for TXA 2 as an autocrine or paracrine facilitator of cytokine synthesis (26) . However, other results suggest that the relation between monocyte eicosanoid and cytokine production probably reflects a balance between the opposing effects of TXA 2 and PGE 2 (26) . Because nϪ3 fatty acids inhibit PGE 2 synthesis also, inhibition of TXA 2 synthesis may provide only one element of a complex mechanism responsible for inhibition of cytokine synthesis by nϪ3 fatty acids.
DIETARY CONSIDERATIONS
When fortifying diets with either EPA, ETA, or both with therapeutic or health-enhancing intent, the background nϪ6 PUFA content of the diet is a key issue. The competitive interactions between nϪ6 and nϪ3 dietary fatty acids that determine the cellular content of the long-chain, highly unsaturated nϪ6 and nϪ3 fatty acids such as AA and EPA have been studied and well described mathematically (5, 27) . When competition from the major dietary PUFA, LA, was specifically examined, it was observed that higher tissue concentrations of EPA and ETA occurred when these fatty acids were ingested within diets of lower LA content (16, 28) . In at least the United States and Australia, the widespread dietary use of LA-rich oils such as soybean, corn, sunflower, and safflower oils results in intakes of LA at Ϸ7-8% of dietary energy (29, 30) . Whether nϪ3 or nϪ9 fats are considered for use as components of foodstuffs or as dietary supplements, the LA content of the modern Western diet merits attention because of its negative effect on tissue concentrations of nϪ3 and nϪ9 fatty acids.
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FUTURE ROLE OF DIETARY POLYUNSATURATED FATTY ACIDS IN THERAPIES FOR INFLAMMATORY DISORDERS
A beneficial clinical effect of dietary supplementation with fish oil on rheumatoid arthritis was observed in at least 11 double-blind, placebo-controlled studies, and in the studies in which drug use was examined, there was partial sparing of nonsteroidal antiinflammatory drug use [summarized in references 31 and 32 and discussed in detail by Kremer in this supplement (33) ]. Common features of the clinical studies that may have moderated the size of the effects observed were that 1) all studies were conducted against unmodified Western diets, ie, diets high in LA, and 2) the usual antiinflammatory and antirheumatic medications were used in addition to fish oil in amounts likely to confer maximum suppression of their common molecular and cellular targets.
The first issue could be addressed by substituting vegetable oils rich in monounsaturated fatty acids for the current oils rich in LA and, preferably, by also using oils with substantial ALA content. The second issue could be addressed by optimizing the possible additive effects of drug-diet combinations. Antiinflammatory drug use could be decreased in some patients with rheumatoid arthritis in concert with increased fish-oil ingestion if both the drug and fish oil are exerting their therapeutic effects through the same molecular actions, eg, inhibition of PGE 2 and TXA 2 production. This might also apply to new drugs or new treatment modalities that aim to suppress cytokine concentrations, ie, there may be an opportunity for beneficial additive effects with fish-oil supplementation or any other dietary approach to increasing intake of nϪ3 fats. Similar arguments apply to use of ETA with drugs that target LTB 4 synthesis. Thus, the possibility exists for drug-diet interactions that confer greater antiinflammatory benefits than either agent alone or similar antiinflammatory effects with less toxicity (Figure 5) . Investigation of potentially beneficial interactions will require greater knowledge of the dose-response effects for both the drug (including biological agent therapies) and the dietary intake of nϪ3 PUFAs.
